Business Wire

Thales Unveils PureFlyt, the Brain of Tomorrow’s Aircraft

25.11.2019 21:33:00 EET | Business Wire | Press release

Share

Innovdays -Thales is unveiling PureFlyt, the Flight Management System (FMS) of the future, specifically designed to efficiently manage aircraft in a connected aerospace ecosystem and in increasingly crowded skies. Indeed, with the global commercial aircraft fleet forecast to double by 2030, and the use of drones set to rapidly grow, we will be entering an era in which millions of aircraft movements are recorded each day.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191125005715/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

© Thales

Combining extensive knowledge of Avionics, Connectivity, Air Traffic management and 40-year Flight Management System expertise, Thales has developed PureFlyt, an entirely connected FMS, designed to offer airframers and airlines the best combination of safety, security, and fuel and operations efficiency. PureFlyt will allow crews to make better decisions using more sources of information, will bring improved performance and reactivity to the aircraft during complex phases of flight and will calculate alternative trajectories in real time to propose or react quickly to changes of plan. Providing pilots with the right information at the right time heightens trust in the computed trajectory, enhancing efficiency and reducing pilot workload throughout all flight phases.

One of the core innovations making PureFlyt a game changer in the FMS world is its ability to draw on both onboard and open-world data, such as weather information. By combining the integrity of the FMS and the agility and power of Electronic Flight Bag flight functionalities, aircraft trajectory can be permanently controlled, adapted and enhanced, resulting in optimised flight, decreased fuel consumption and improved passenger comfort.

While being a technological breakthrough, PureFlyt enjoys an unparalleled maturity level. Using massive testing and artificial intelligence technologies to simulate 2 billion test cases enabled accumulating an invaluable experience, equivalent of 100 million actual flight hours.

Cyber-secure by design, PureFlyt has also been designed to be future-proof, accommodating the implementation of concepts such as the Initial 4D (I4D) trajectory management methods currently being researched by SESAR (Single European Sky ATM Research) in the EU and NextGen in the US. By increasing the accuracy of flight in four dimensions, the fourth dimension being time, PureFlyt will enable more effectiveness in maintaining optimal distance between aircraft, particularly in the demanding phases of departure and approach.

PureFlyt will be available for entry into service in 2024, for both linefit and retrofit.

“In the air, the digital revolution has only just begun. A paradigm shift in onboard cockpit electronics is taking place in the connected airspace and PureFlyt is at the forefront of this digital new age, leading the next generation of Flight Management System that truly makes the aircraft a node of connectivity. By computing and sharing vast amounts of data, PureFlyt will make flights safer, greener, easier for the pilots to manage, more profitable for airlines and, all this, ultimately for the full benefits of passengers” declared Jean-Paul Ebanga, Thales Vice-President Flight Avionics.

For more information please visit:
https://www.thalesgroup.com/en/group/magazine/quantum-leap-flight-management

About Thales

The people we all rely on to make the world go round – they rely on Thales. Our customers come to us with big ambitions: to make life better, to keep us safer. Combining a unique diversity of expertise, talents and cultures, our architects design and deliver extraordinary high technology solutions. Solutions that make tomorrow possible, today. From the bottom of the oceans to the depth of space and cyberspace, we help our customers think smarter and act faster - mastering ever greater complexity and every decisive moment along the way.

Thales generated revenues of €19 billion in 2018 with 80,000 employees in 68 countries.

PLEASE VISIT

Thales Group
Thales Press
Download HD photos

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PRESS
Thales, Media Relations
Civil Aerospace
Giaime Porcu
+33 1 57 77 92 18
giaime.porcu@thalesgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye